Analysis of the Cochrane Review: Fibrates for secondary prevention of cardiovascular disease and stroke

详细信息    查看全文

• 作者：Gilberto Pires da Rosa^a ; Diogo Libâ ; nio^b ; Luí ; s Filipe Azevedo^c ; ^d ; ^e ; ^{lazevedo@med.up.pt} ; ^{lfazevedo55@gmail.com}
• 关键词：Fibrates ; Cardiovascular events ; Stroke ; Secondary prevention ; Systematic review
• 刊名：Revista Portuguesa de Cardiologia (English Edition)
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：36
• 期：1
• 页码：55-58
• 全文大小：209 K
• 卷排序：36

文摘

The influence of fibrates on cardiovascular risk has been the focus of several clinical trials. This Cochrane Collaboration Systematic Review evaluated the efficacy of fibrates for secondary prevention of cardiovascular events and stroke, analyzing 13 randomized controlled trials, in a total of 16 112 participants with a history of cardiovascular disease. Fibrates showed a protective effect for the composite outcome of non-fatal stroke, non-fatal myocardial infarction (MI) and vascular death, mainly due to reduction in the risk of non-fatal or fatal MI. Nonetheless, these results largely relied on studies including clofibrate, a drug withdrawn from the market in 2002. No statistically significant differences regarding adverse events were found between fibrates and placebo. Although insufficient to support the routine prescription of fibrates in this setting, this evidence should be taken into account when deciding on lipid-modifying therapy in dyslipidemic patients with a history of cardiovascular disease.